FDA approves Bristol Myers Squibb's schizophrenia drug
WEB3 days ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB4 days ago · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets …
WEB2 days ago · Bristol Myers Squibb shares surged in premarket trading and were up 2% about 30 minutes into Friday's session, but remain slightly negative for 2024. TradingView Read the original article on ...
Pharmaceutical press releases & news - Bristol Myers Squibb
WEBSep 15, 2024 · Explore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines and research innovation, our partnerships, our people, and our Foundation efforts as we work to support patients fighting serious disease.
Bristol Myers Squibb - News
WEBStay updated on the latest news from Bristol Myers Squibb, a global biopharmaceutical company dedicated to developing and delivering innovative medicines for serious diseases.
Bristol Myers Squibb - News
WEBSep 9, 2024 · Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia …
WEB3 days ago · Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
Absence of Black Box Warning For Bristol Myers' Schizophrenia …
WEB2 days ago · On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Bristol Myers second-quarter results beat expectations, helped by …
WEBJul 26, 2024 · Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its...
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy ...
WEBOct 24, 2023 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...